Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479135 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL693557 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL216035 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL8361882 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL20552191 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL235344 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL6682662 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL5699292 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL1053630 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 | |
| SCHEMBL11552545 | 1.00 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| US-20180362475-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-12-20 | — | — | US | disclosed |
| US-10117878-B2 | Ligands for nematode nuclear receptors and uses thereof | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-06 | — | — | US | disclosed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9814700-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3217982-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-09-20 | — | — | EP | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2017-02-23 | — | — | US | disclosed |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION | 2016-12-22 | — | — | US | disclosed |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050282768-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005117910-A2 | PURINE DERIVATIVES AS ADENOSINE A1 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005110980-A2 | ARYL SULFONES AND USES RELATED THERETO | AMGEN, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005054406-A1 | ADDITIVE COMPONENTS FOR LIQUID CRYSTALLINE MATERIALS | ROLIC AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282768-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | ADORA2A, ADORA1, ADORA3 | KDM1A 2670/4885MAPT 4595/4885HSD11B1 3212/4885 |
| US-10117878-B2 | Ligands for nematode nuclear receptors and uses thereof | NR4A1, NR0B1, NR1H2 | KDM1A 2231/4885MAPT 4726/4885HSD11B1 753/4885 |
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | KDM1A 4013/4885MAPT 3617/4885HSD11B1 1236/4885 |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | KDM1A 1944/4885MAPT 3482/4885HSD11B1 274/4885 |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | PTGIR, ADORA1, PDE3A | KDM1A 1060/4885MAPT 4697/4885HSD11B1 1531/4885 |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | ARSA, STS, SULT2A1 | KDM1A 2460/4885MAPT 4435/4885HSD11B1 162/4885 |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | KDM1A 677/4885MAPT 3890/4885HSD11B1 289/4885 |
| US-20180362475-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | AIFM2, BAD, AIFM1 | KDM1A 4013/4885MAPT 3617/4885HSD11B1 1236/4885 |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | HSD17B1, HSD3B1, HSD11B1 | KDM1A 3313/4885MAPT 3890/4885HSD11B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.